April 22 168 people in the country have developed thrombosis symptoms after receiving a Coronavirus vaccine jointly developed by AstraZeneca Pharmaceuticals and Oxford University, 32 of whom died, according to figures updated by the U.K. Medicines and Healthcare Products Administration.
As of April 14, 21.2 million people in the UK had been vaccinated against the first dose of AstraZeneca’s Coronavirus vaccine, according to the Medicines and Healthcare Products Authority. Of the 168 people with thrombosis symptoms, 75 were men and 93 were women. Of these, 77 were cerebral sinus thrombosis, and 91 others developed severe thrombosis associated with platelet reduction.
However, the agency said that “based on this ongoing assessment, the current recommendation remains that for most people, the benefits of vaccination outweigh the risks”.
On the basis of the agency’s recommendations, the British government this month agreed to provide the majority of people under the age of 30 with alternatives to AstraZeneca’s Coronavirus vaccine, as conditions permit.
The main people currently vaccinated in the UK are the Coronavirus vaccine developed by Pfizer Inc. of the United States in partnership with The German biotech company, as well as Coronavirus vaccine of AstraZeneca.
In response to the risks of vaccination against Coronavirus vaccine at a video press conference on the 15th of this month, the Director of the World Health Organization’s Regional Office for Europe, Klug, again stressed that the benefits of vaccination outweigh the risks.
Of the 200 million people worldwide who have been vaccinated against AstraZeneca’s Coronavirus, only a handful have a rare clotting disorder; the risk of thrombosis from Coronavirus is now much higher than after the AstraZeneca vaccine; and “there is no doubt that AstraZeneca’s Coronavirus vaccine is effective in reducing new coronary serious illness and deaths,” Kluger said.
